AMSTERDAM, The Netherlands, January 28 /PRNewswire-FirstCall/ --
- European Patent Office Grants Patent for Treatment of Non-Alcoholic Steatotic Hepatitis
AMT (Euronext: AMT), a leader in the field of human gene therapy, today announced that the European Patent Office (EPO) has granted the company an important patent for the treatment of Non-Alcoholic Steatotic Hepatitis (NASH) with its lead product AMT-11. AMT has a similar patent pending with the U.S. Patent and Trademark Office.
The most common liver disorder in the Western world, non-alcoholic fatty liver disease (NAFLD), affects 20 to 40 percent of the general population. At least 11 percent of NAFLD patients will develop NASH, a very serious inflammatory liver disease for which there is no therapy and affects many millions in the developed world.
AMT-011, NAFLD, NASH and the metabolic syndrome
AMT-011 is currently in its last phase of clinical development for the treatment of lipoprotein lipase (LPL) deficiency that is associated with very high circulating triglyceride (fat) levels. The product consists of an AAV-based vector that delivers the LPL gene to the muscle, leading to long-term expression of the therapeutic protein, lipoprotein lipase.
The patented invention is related to the observation that expression of
AMT-011 in muscle causes a reduction of the liver triglyceride content by
redistributing triglycerides from the liver to the peripheral muscles where
it is metabolized. NAFLD and NASH are closely related to the pathogenesis
of the "metabolic syndrome". This latter condition is characterized by
central obesity, increase of serum triglycerides and insulin resistance,
and is a major cause of diabetes and coronary vascular disease in the
Western world. Recent epidemiological studies published in the journals
Gastroenterology and Annals of Hepatology show that the prevalence of NAFLD
in the general population is extremely high. Over 60 million adult
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2008 PR Newswire.
All rights reserved